Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aberrant activation of B cells in patients with rheumatoid arthritis.
Lindenau S, Scholze S, Odendahl M, Dörner T, Radbruch A, Burmester GR, Berek C. Lindenau S, et al. Among authors: burmester gr. Ann N Y Acad Sci. 2003 Apr;987:246-8. doi: 10.1111/j.1749-6632.2003.tb06055.x. Ann N Y Acad Sci. 2003. PMID: 12727646 Review. No abstract available.
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
Baker KF, Spierings J, Brom M, Radstake T, Smith E, Weiss R, Burmester GR; FOREUM Boot Camp Working Group member. Baker KF, et al. Among authors: burmester gr. Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39532310 Free article. No abstract available.
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Smolen JS, Trefler J, Racewicz A, Jaworski J, Zielińska A, Krogulec M, Jeka S, Wojciechowski R, Kolossa K, Dudek A, Krajewska-Włodarczyk M, Hrycaj P, Klimiuk PA, Burmester GR, Kim S, Bae Y, Yang G, Jung Y, Hong J, Keystone E. Smolen JS, et al. Among authors: burmester gr. RMD Open. 2024 Oct 18;10(4):e004514. doi: 10.1136/rmdopen-2024-004514. RMD Open. 2024. PMID: 39424404 Free PMC article. Clinical Trial.
[Head-to-head studies in rheumatology].
Burmester GR, Behrens F. Burmester GR, et al. Z Rheumatol. 2024 Oct;83(8):607-608. doi: 10.1007/s00393-024-01578-9. Epub 2024 Oct 16. Z Rheumatol. 2024. PMID: 39412653 German. No abstract available.
Correction to: Collating the voice of people with autoimmune diseases: Methodology for the third phase of the COVAD studies.
Kadam E, Javaid M, Sen P, Saha S, Ziade N, Day J, Wincup C, Andreoli L, Parodis I, Tan AL, Shinjo SK, Dey D, Cavagna L, Chatterjee T, Knitza J, Wang G, Dalbeth N, Velikova T, Battista S, Cheng K, Boyd P, Kobert L, Gracia-Ramos AE, Mittal S, Makol A, Gutiérrez CET, Caballero-Uribe CV, Kuwana M, Burmester GR, Guillemin F, Nikiphorou E, Chinoy H; COVAD Study group; Agarwal V, Gupta L. Kadam E, et al. Among authors: burmester gr. Rheumatol Int. 2024 Dec;44(12):3157-3162. doi: 10.1007/s00296-024-05692-4. Epub 2024 Oct 14. Rheumatol Int. 2024. PMID: 39400562 Free PMC article. No abstract available.
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Yu KS, Ryu H, Shin D, Park M, Hwang J, Moon SJ, Kim MG, Keystone E, Smolen JS, Kim S, Bae Y, Jeon D, Jang J, Yang G, Bae J, Lee J, Burmester GR. Yu KS, et al. Among authors: burmester gr. Expert Opin Biol Ther. 2024 Jul;24(7):681-689. doi: 10.1080/14712598.2024.2321360. Epub 2024 Jun 21. Expert Opin Biol Ther. 2024. PMID: 38905143 Clinical Trial.
889 results